

Impact of COVID-19 on smell and taste

1 Self-reported taste and smell disorders in patients with COVID-19: distinct 2 features in China

3 Jia Song, M.D., Ph.D.^{1*}, Yi-ke Deng, M.D., Ph.D.^{1*}, Hai Wang, M.D., Ph.D.^{1*}, Zhi-Chao Wang, M.D., Ph.D.¹, Bo Liao, M.D., Ph.D.¹, Jin Ma, M.D.,
4 Ph.D.¹, Chao He, M.D., Ph.D.¹, Li Pan, M.D., Ph.D.¹, Yang Liu, M.D., Ph.D.¹, Isam Alobid, M.D., Ph.D.², De-Yun Wang, M.D., Ph.D.³, Ming
5 Zeng, M.D., Ph.D.^{1†}, Joaquim Mullol, M.D., Ph.D.^{2†}, Zheng Liu, M.D., Ph.D.^{1†}

6 ¹ Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and
7 Technology, Wuhan, P.R. China

8 ² Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain

9 ³ Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

10 Abstract

11 **Objectives:** We aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their
12 presentation as the first symptom of the disease and their association with the severity of COVID-19.

13 **Methods:** In this retrospective study, 1,206 laboratory-confirmed COVID-19 patients were included and followed-up by telephone call one month
14 after discharged from Tongji Hospital, Wuhan. Demographic data, laboratory values, comorbidities, symptoms, and numerical rating scale scores
15 (0-10) of nasal symptoms were extracted from the hospital medical records, and confirmed or reevaluated by the telephone follow-up.

16 **Results:** From COVID-19 patients (N = 1,172) completing follow-up, 199 (17%) subjects had severe COVID-19 and 342 (29.2%) reported nasal
17 symptoms. The most common nasal symptom was loss of taste (20.6%, median score = 6), while 11.4% had loss of smell (median score = 5). The
18 incidence of nasal symptom including loss of smell and loss of taste as the first onset symptom was <1% in COVID-19 patients. Loss of smell or
19 taste scores showed no correlation with the scores of other nasal symptoms. Loss of taste scores, but not loss of smell scores, were significantly
20 increased in severe vs. non-severe COVID-19 patients. Interleukin (IL)-6 and lactose dehydrogenase (LDH) serum levels positively correlated with
21 loss of taste scores. About 80% of COVID-19 patients recovered from smell and taste dysfunction in 2 weeks.

22 **Conclusion:** In the Wuhan COVID-19 cohort, only 1 out of 10 hospital admitted patients had loss of smell while 1 out 5 reported loss of taste
23 which was associated to severity of COVID-19. Most patients recovered smell and taste dysfunctions in 2 weeks.

24

Impact of COVID-19 on smell and taste

25 **Key words:** Loss of taste; loss of smell; upper respiratory tract; coronavirus disease 2019; severe
26 acute respiratory syndrome coronavirus 2

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Impact of COVID-19 on smell and taste

44 **Introduction**

45 Last December 2019, a cluster of viral pneumonia cases identified as coronavirus disease 2019
46 (COVID-19), was reported in Wuhan, China. Subsequently, severe acute respiratory syndrome
47 coronavirus 2 (SARS-CoV-2) has been identified to be the pathogenic cause of COVID-19 [1-3].
48 This newly recognized illness has spread rapidly throughout Wuhan (Hubei province) to all over
49 the world [4-6]. The diagnosis of the COVID-19 is based on clinical manifestations, contact history
50 report, chest computed tomography (CT) and positive result of nucleic acid test [7-9]. Due to the
51 uncertainty of contact history and the rush to hospitals that could run out of the essential equipment
52 for test during the world-wide pandemic, efforts to identify additional diagnostic or prognostic
53 symptoms of COVID-19 has significant value in mitigating transmission.

54 The clinical spectrum of COVID-19 ranges from asymptomatic to severe ill cases [1, 2, 6, 7,
55 10-12]. The most common symptom of COVID-19 is fever, and other common systemic symptoms
56 include dyspnea, cough, nausea and vomiting, etc [6, 7, 10]. In addition, olfactory and taste
57 disorder have been recently noted in patients with COVID-19. An early study conducted in Italy
58 reported 33.9% of hospitalized COVID-19 patients shown at least one taste or olfactory disorders
59 [13]. Later studies in Europe reported that about 75%-85% COVID-19 patients had olfactory
60 dysfunction and about 70%-88% patients had gustatory dysfunctions [14]. Very recently, similar
61 prevalence of smell and taste disorder has been found in COVID-19 patients in USA [15]. It is
62 indicated that smell or taste change may be a strong predictor for a COVID-19 positive test result
63 and may serve as an early alerting symptom for COVID-19 [16]. However, an early study based
64 on analyzing electronic medical records of 214 patients with COVID-19 in Wuhan, China reported
65 that the ratio of patients complaining of loss of taste and loss of smell was only 5.6% and 5.1%,
66 respectively [17], significantly lower than those reported in Europe and USA. One potential reason

Impact of COVID-19 on smell and taste

67 for the low ratios in China may be related to incomplete medical records of COVID-19 patients
68 under actual emergency situation, which underestimated the incidences of upper airway tract
69 manifestations. Nevertheless, it is also possible that there are different responses to SARS-CoV-
70 2 infection in people with distinct ethnic/culture background. Therefore, more accurate evaluation
71 of upper airway tract manifestations in COVID-19 patients should be conducted to figure out the
72 clinical importance of smell and taste dysfunction in the early diagnosis of COVID-19 for Chinese
73 and to elucidate whether there are different clinical manifestations between patients with distinct
74 ethnic/culture background. Moreover, several important questions remain to be answered. How
75 severe are the upper airway tract symptoms in patients with COVID-19? Is there any correlation
76 between olfactory and taste disorders and other nasal symptoms such as nasal obstruction? Will
77 the severity of olfactory or taste disorder be associated with the severity of COVID-19? Will there
78 be a full recovery of olfactory or taste disorder and how long it will take?

79 In this retrospective study, we investigated the COVID-19 patients discharged from Tongji
80 Hospital, the largest designated hospital to treat patients with COVID-19, in Wuhan. Integrating
81 medical record analysis and reevaluation of upper airway symptoms by the telephone follow-up,
82 we aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss
83 of smell and taste, as well as their presentation as the first symptom of the disease and their
84 association with the severity of COVID-19.

85

86 **Methods**

87 **Study participants**

Impact of COVID-19 on smell and taste

88 A single center, retrospective cohort study was conducted in Wuhan, China, where COVID-
89 19 initially outbreaked. We obtained the electronic medical records for discharged COVID-19
90 patients between January 27, 2020 and March 10, 2020, who initially admitted to the Tongji
91 Hospital. The diagnosis was made on the basis of guidance for diagnosis and management of
92 COVID-19 released by WHO [3]. A laboratory-confirmed case of COVID-19 was defined as
93 having positive result on real-time reverse-transcriptase-polymerase-chain-reaction assay of nasal
94 and pharyngeal swab specimens. Only laboratory-confirmed cases were included in the study. All
95 patients were followed up by telephone on the 30th (± 2) day after discharge. The study was
96 approved by Tongji Hospital Research Ethics Committee.

97

98 **Clinical characteristic, laboratory assessment, and telephone follow-up**

99 The degree of severity of COVID-19 was defined as severe and non-severe at the time of
100 admission using the American Thoracic Society guidelines for community-acquired pneumonia
101 [18]. The information of demographic characteristics, systemic major symptoms, and major
102 commodities related to COVID-19 were extracted from electronic medical records. In addition,
103 the results of laboratory assessments on admission were also collected from electronic medical
104 records. All laboratory testing was performed according to the clinical care needs of the patients.
105 Laboratory assessments consisted of a complete blood routine, blood biochemistry, coagulation
106 function, infection biomarkers and immune function. All data were entered into a computerized
107 database and cross-checked.

108 The airway comorbidities and nasal symptoms, the date of symptomatic onset, and numerical
109 rating scale scores and duration days of symptoms were obtained based on the hospital medical

Impact of COVID-19 on smell and taste

110 records and were confirmed and reevaluated by the telephone follow-up. The severity of upper
111 respiratory tract symptoms was scored by patients on a numerical rating scale of 0-10, with 0 being
112 “no complaint whatsoever” and 10 being “the worst imaginable complaint” [19, 20]. Six major
113 symptoms of upper respiratory tract were focused on: nasal obstruction, rhinorrhea, nasal itching,
114 sneezing, loss of smell, and loss of taste. The severity of loss of smell and loss of taste was defined
115 as follows: Mild = score 0-3; Moderate= score 4-7; Severe = score 8-10 [19, 20]. The difference
116 between the symptom of loss of smell and loss of taste was explained to the patients very carefully
117 during telephone follow-up according to previous studies [21, 22]. The detailed questionnaire
118 showed in this article’s Online Supplement.

119

120 **Statistical Analysis**

121 For continuous variables, Mann-Whitney U 2-tailed test was used for between-group
122 comparison. Chi-square test was applied to compare the difference in proportions between groups.
123 Spearman test was used for correlation analysis. Difference was considered to be statistically
124 significant if a P value was less than 0.05. These statistical analyses were performed by using an
125 IBM SPSS 22.0 package (SPSS Inc, Chicago, IL).

126

127 **Results**

128 **Demographic and clinical characteristics**

129 Totally 1,206 patients were enrolled and 1,172 of them completed questionnaires. The follow-
130 up rate was 97.2%. Reasons of the lost cases included: refusal to answer questions for personal

Impact of COVID-19 on smell and taste

131 reasons (n = 23); unable to provide accurate information (n = 6); phone calls were not answered
132 (n = 5). The demographic and clinical characteristics of 1,172 patients are shown in Table 1. The
133 median age was 61 years (IQR, 48-68), and 577 (49.2%) were men. The ratio of severe cases was
134 17% (199/1172).

135 Of the 1172 cases, 399 (25.1%) reported with at least one comorbidity, and 17.3% having one
136 or more respiratory comorbidities, including allergic rhinitis (AR, 9.8%), chronic rhinosinusitis
137 (CRS, 6.1%), asthma (2.5%) and chronic obstructive pulmonary disease (COPD, 0.9%). The
138 frequency of patients with at least one nasal symptom was up to 29.2%, including nasal obstruction
139 (8.6%; median score, 3), rhinorrhea (10.3%; median score, 3), nasal itching (4.9%; median score,
140 2), sneezing (11.0%; median score, 2), loss of smell (11.4%; median score, 5), and loss of taste
141 (20.6%; median score, 6). The incidence of symptom reported as the first onset symptom was <
142 1% for each individual nasal symptom, including loss of smell and taste. No difference in
143 frequency of patients with loss of smell or taste disorder was found between severe and non-severe
144 COVID-19 cases (Fig 1, A). The scores of loss of taste but not smell were significantly higher in
145 the patients with severe vs. non-severe COVID-19 (7 [5- 9] vs. 6 [4- 8]; $P = 0.03$) (Fig 1, B). No
146 difference in frequency or score for the other nasal symptoms was found between severe and non-
147 severe disease. The data is shown in Table 1 and Fig 1.

148 Sense of smell and taste are determined by the chemosensory system of the upper respiratory
149 tract, which could be impacted by the nasal dysfunction [22]. Hence, we analyzed the relations
150 between the scores of loss of taste and smell and other nasal symptoms. We failed to find any
151 correlation between loss of taste or loss of smell scores and scores of the other nasal symptoms
152 (Fig E1 in the Online Supplement). However, loss of taste showed mild positive correlation with
153 loss of sense of smell ($\rho = 0.25$, $P < 0.01$) (Fig E1 in the Online Supplement).

Impact of COVID-19 on smell and taste

154 Given the possibility that some patients might not well distinguish the taste and smell disorder
155 [21, 22], we compared the differences among the patients only with one smell or taste disorder,
156 the patients with both smell and taste disorder, and the patients without any of these two symptoms.
157 We found that the patients without loss of smell and taste were significant elder than the patients
158 in the other two groups (62 [48-69] years vs 59 [46-67] years, 57.5 [42.75-66] years, $P = 0.03$).
159 No other difference of clinical characteristics and laboratory measurements was found among the
160 patients in three groups. The data is shown in Table E1 in the Online Supplement.

161

162 **The recovery of olfactory and taste function**

163 We found that 82.1% (110/134) of patients with loss of sense of smell and 95.5% (231/242)
164 of patients with loss of taste recovered in one month after discharge. The symptomatic duration
165 days showed no difference between the patients with loss of smell and taste (8 [6-13.25] vs 7 [5-
166 14] days, $P = 0.52$) (Fig 1, C). Most of them recovered in 14 days after onset of symptom (Fig 1,
167 D). No difference in recovery frequency of smell function was found between severe (83.3%) and
168 non-severe cases (81.8%) ($P = 0.99$) (Table 1). As to taste disorder, 95.3% patients with severe
169 COVID-19 and 95.5% patients with non-severe COVID-19 recovered, and no difference showed
170 neither ($P = 0.99$) (Table 1). The data is also shown in Table 1. Due to the limited number of
171 patients with unrecovered symptoms, we did not compare the differences between recovered and
172 unrecovered patients with loss of smell or loss of taste.

173

Impact of COVID-19 on smell and taste

174 **Clinical characteristics of COVID-19 patients with different severity of taste and smell** 175 **disorder**

176 Since the taste disorder was the most common upper respiratory tract symptoms and showed
177 positive correlation to the symptom of loss of smell, we subsequently compared the differences
178 among the COVID-19 patients with different severity of loss of taste (Table 2) and loss of smell
179 (Table 3). First, we divided 242 COVID-19 cases with loss of taste into mild (score, 1-3; 19.0%),
180 moderate (score, 4-7; 48.8%) and severe (score, 8-10; 32.2%) group by symptom scores, similar
181 to the visual analogue scale system of nasal symptoms [19, 20]. More COVID-19 cases with severe
182 illness were found in the severe loss of taste group than in the moderate loss of taste group (26.9%
183 vs 12.7%, $P = 0.03$). The symptom duration of loss of taste was significantly longer in moderate
184 and severe taste dysfunction group as compared to the mild taste dysfunction group (8 days [6-
185 13.25], 10 days [5-15] vs 5 days [3.5-8], $P < 0.01$) (Fig 2). In addition, serum levels of interleukin-
186 6 (IL-6) and lactate dehydrogenase (LDH) were significantly increased in patients with severe
187 compared to mild and moderate loss of taste group (Table 2). Levels of IL-8 were significantly
188 increased in severe and moderate compared to mild loss of taste group (Table 2). The
189 characteristics of the patients with different severity of taste disorder are shown in Table 2. In
190 addition, IL-6 and LDH showed mild positive correlations to the symptom scores of loss of taste
191 ($\rho = 0.15$, $P = 0.03$; $\rho = 0.21$, $P < 0.01$, respectively; Fig 3).

192 As to the comparison among different severity of loss of smell, we divided the 134 patients
193 with loss of sense of smell into mild (score, 1-3, 23.9%), moderate (score, 4-7; 35.8%) and severe
194 (score, 8-10; 40.3%) group. No prominent difference in clinical and laboratory measurements was
195 found among the patients with different severity (Table 3 and Fig 2).

Impact of COVID-19 on smell and taste

196 **Discussion**

197 To the best of our knowledge, this is the first study on detailed information of manifestations
198 of the upper respiratory tract of the hospitalized patients with COVID-19 in China. We reported
199 the manifestations of upper respiratory tract in a cohort of 1,172 patients with laboratory-
200 confirmed COVID-19 in Wuhan, China. Overall, 17% subjects were categorized as severe
201 COVID-19, this percentage being similar with previous reports from China [7, 10]. Most of the
202 common systemic signs and symptoms of disease such as fever, fatigue, and anorexia, etc. reported
203 in previous studies were also observed in our cohort [2, 7, 10]. Nevertheless, under urgent
204 admission of COVID-19 patients, compared to systemic symptoms and comorbidities, nasal
205 symptoms and upper airway comorbidities were very likely incompletely documented and
206 underestimated in previous studies based on medical record analysis [7, 23]. In order to overcome
207 this limitation in real-world setting, we did recalled questionnaires by phone call to reevaluate the
208 presence of airway comorbidities, and frequency and severity of nasal symptoms. As a result, the
209 frequencies of COVID-19 patients with AR and CRS were 9.8% and 6.1%, respectively. Previous
210 studies have reported that adult AR and CRS in general population in China were 17.6% and 8%,
211 respectively, these being higher than the reported for COVID-19 [24, 25]. Recent studies indicate
212 that the increasing eosinophils may be an indicator of COVID-19 improvement [26, 27]. Hence,
213 we cannot rule out the possibility that the comorbidities of allergic and eosinophilic diseases such
214 as AR might be potential protective factors for severe COVID-19.

215 Here, we found that upper respiratory tract symptoms were identified in 29.2% patients with
216 COVID-19, with nasal obstruction, rhinorrhea, nasal itching and sneezing presenting in
217 mild/moderate severity and loss of smell and taste presenting in moderate/severe severity. All of
218 these upper respiratory tract symptoms have been commonly reported in other respiratory viral

Impact of COVID-19 on smell and taste

219 infection, such as influenza and rhinovirus [28-30]. Our data suggest that similar with the common
220 respiratory viruses, SARS-CoV-2 may be able to infect upper respiratory tract mucosa and cause
221 similar symptoms [22, 29, 31]. In addition, the result in our Wuhan cohort revealed that the self-
222 reported symptoms of upper respiratory tract were not the first symptom in most COVID-19
223 patients, doubting the diagnostic value of these symptoms preceding the onset of full-blown
224 clinical disease. However, our study only included hospitalized COVID-19 patients while the
225 clinical manifestations of COVID-19 can range from asymptomatic infection to severe pneumonia
226 [2, 7, 32]. Further investigations on non-hospitalized infected patients and patients with likely
227 sudden onset anosmia will help to determine the role of upper airway symptoms, particular loss of
228 smell and taste, as a screening tool for COVID-19.

229 Interestingly, the loss of taste and smell were the most common upper respiratory tract
230 symptoms observed in COVID-19 patients in Wuhan, with 17.5% patients having only smell or
231 taste disorder and 7.3% patients having both symptoms. By integrating medical record analysis
232 and follow-up confirmation and reevaluation after discharge, we reported higher rates of smell and
233 taste disorder in the hospitalized patients than an early report from Wuhan, which relied on medical
234 record analysis only and had a smaller sample size [17]. However, the rates of smell and taste
235 disorder in our cohort were much lower than those reported in Europe and America [13-16, 33]. It
236 may be related to the different characteristics of COVID-19 patients. In our study, asymptomatic
237 patients and non-hospitalized patients with mild symptoms were not included. It is also likely that
238 people with distinct ethnic/culture background may have different response to SARS-CoV-2
239 infection. Previously, no large-sample-size investigation of olfactory and taste disorder in the
240 disease caused by either SARS-CoV-1 or middle east respiratory syndrome coronavirus, that
241 belongs to the same family of coronaviruses, was undertaken. A case report revealed the olfactory

Impact of COVID-19 on smell and taste

242 disorder in a patient infected with SARS- CoV-1 [34]. Nevertheless, olfactory and taste disorders
243 are well known to be widely associated with a number of viral infections [35, 36]. The frequency
244 of patients with loss of smell in the present study was similar to that of post-viral olfactory
245 dysfunction (PVOD) caused by the common respiratory virus, such as influenza with a ratio of
246 about 17% [29, 31]. PVOD can be caused by mechanical obstruction of odorant transmission due
247 to edema of nasal mucosa, and/or the inflammatory impairment of the olfactory neuroepithelium
248 and even central nervous systems [22, 31, 37, 38]. We found that the scores of taste and smell
249 dysfunction showed no correlation with the scores of the other nasal symptoms including nasal
250 obstruction, disfavoring a role of mechanical obstruction in the dysfunction of smell and taste. In
251 fact, the symptom scores indicate that COVID-19 patients suffer from mild/moderate nasal
252 obstruction and rhinorrhea, despite moderate/severe olfactory and taste disorder. SARS-CoV-1 has
253 demonstrated a transneural penetration through the olfactory bulb in mice model [39]. Angiotensin
254 converting enzyme 2, which is used by SARS-CoV-1 and SARS-CoV-2 to invade the host cells,
255 is widely expressed on the epithelial cells in nasal and oral cavity [40, 41]. These evidence suggest
256 a neurological involvement in smell and taste disorder caused by SARS- CoV-2 infection. In this
257 study, COVID-19 patients with severe illness had more severe taste disorder. In addition, serum
258 levels of IL-6, a pro-inflammatory cytokine, were elevated in patients with severe taste disorder,
259 and positively correlated with the loss of taste scores. Previous studies demonstrated that the pro-
260 inflammatory cytokines were able to impair the function of taste buds directly, thus leading to taste
261 dysfunction [42, 43].

262 The present study revealed that 95.5% patients with loss of taste and 82.1% patients with loss
263 of smell recovered spontaneously, and most of them in 2-week time, although the severe
264 impairment of olfactory and smell function may lead to delayed recovery. The spontaneous

Impact of COVID-19 on smell and taste

265 recovery may be a result of regeneration of the damaged olfactory epithelium and taste buds [44].
266 Previously, oral and topical corticosteroids have been proposed to treat viral-associated olfactory
267 loss. However, systemic corticosteroids may impair the viral clearance. Given to the high rate of
268 spontaneous recovery of olfactory and taste function, it seems that there is no need to use
269 corticosteroids for treating olfactory and smell disorder in patients with COVID-19, although their
270 administration can be continued to treat comorbidities such as AR and CRS [45].

271 We have to acknowledge that there are several limitations of this study. First, the self-reported
272 and recalled symptoms and comorbidities without diagnostic testing, especially for the
273 symptomatic information of loss of smell and taste obtained over a month after onset, might
274 contribute to under- or over- estimation of the prevalence of these symptoms, and the strength of
275 association with the clinical outcomes. Second, the self-report and questionnaire-based evaluation
276 could not clearly discriminate the symptoms of loss of smell and taste in patients with COVID-19.
277 It is the inherent limitation of the study based on self-reported data. Three, it was impossible to
278 include the fatal cases due to the incomplete medical records regarding upper airway symptoms
279 and comorbidities, and impossible telephone recall. Fourth, asymptomatic patients and non-
280 hospitalized patients with mild symptoms were missed in this study. Fifth, we cannot preclude the
281 influence of AR and CRS comorbidity on the presentation of upper airway symptoms during
282 COVID-19. However, most of our patients claimed that their primary AR or CRS were under
283 control at baseline and we found no difference in upper airway symptoms between patients with
284 and without AR or CRS comorbidity (data not shown).

285

286 **Conclusion**

Impact of COVID-19 on smell and taste

287 To the best of our knowledge, this is the largest retrospective cohort study focusing on the
288 symptoms of upper respiratory tract in patients with COVID-19 in China. We found that nearly
289 one third of COVID-19 patients got the upper respiratory tract symptoms. Loss of smell affected
290 one out of ten patients with COVID-19 while loss of taste was the most common upper respiratory
291 tract symptom affecting one out of five patients, being associated with the severity of COVID-19
292 infection. Finally, about 80% of patients spontaneously recovered from olfactory and taste
293 dysfunction in a short term of 2 weeks.

294

295

296

297

298

299

300

301

302

303

304

305

306

Impact of COVID-19 on smell and taste

307 **References**

- 308 [1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
309 associated with a new coronavirus of probable bat origin. *Nature* 2020;579(7798):270-3.
- 310 [2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
311 with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506.
- 312 [3] Organization WH. Clinical management of severe acute respiratory infection when novel
313 coronavirus (2019-nCoV) infection is suspected: interim guidance. January 28, 2020
314 ([https://www.who.int/docs/default-source/
315 coronaviruse/clinical-management-of-novel-cov.pdf](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf)).
- 316 [4] Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First
317 known person-to-person transmission of severe acute respiratory syndrome coronavirus 2
318 (SARS-CoV-2) in the USA. *Lancet* 2020;395(10230):1137-44.
- 319 [5] Pung R, Chiew CJ, Young BE, Chin S, Chen MI, Clapham HE, et al. Investigation of three
320 clusters of COVID-19 in Singapore: implications for surveillance and response measures.
321 *Lancet* 2020;395(10229):1039-46.
- 322 [6] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically
323 ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
324 retrospective, observational study. *Lancet Respir Med* 2020.
- 325 [7] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
326 Coronavirus Disease 2019 in China. *N Engl J Med* 2020.
- 327 [8] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
328 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
329 2020;395(10229):1054-62.

Impact of COVID-19 on smell and taste

- 330 [9] The Seventh Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and
331 Treatment Ghidance. Available at:
332 [http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.sht](http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.shtm)
333 [ml](#).
- 334 [10] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
335 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
336 JAMA 2020.
- 337 [11] Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients
338 coinfecting with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol
339 2020.
- 340 [12] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
341 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
342 descriptive study. Lancet 2020;395(10223):507-13.
- 343 [13] Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported
344 olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect
345 Dis 2020.
- 346 [14] Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al.
347 Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms
348 of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch
349 Otorhinolaryngol 2020.
- 350 [15] Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory
351 dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum
352 Allergy Rhinol 2020.

Impact of COVID-19 on smell and taste

- 353 [16] Roland LT, Gurrola JG, 2nd, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom-
354 based predictive model for COVID-19 diagnosis. *Int Forum Allergy Rhinol* 2020.
- 355 [17] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of
356 Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*
357 2020.
- 358 [18] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and
359 Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice
360 Guideline of the American Thoracic Society and Infectious Diseases Society of America.
361 *Am J Respir Crit Care Med* 2019;200(7):e45-e67.
- 362 [19] Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European
363 Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology* 2020;58(Suppl
364 S29):1-464.
- 365 [20] Zeng M, Wang H, Liao B, Wang H, Long XB, Ma J, et al. Comparison of efficacy of
366 fluticasone propionate versus clarithromycin for postoperative treatment of different
367 phenotypic chronic rhinosinusitis: a randomized controlled trial. *Rhinology*
368 2019;57(2):101-9.
- 369 [21] Malaty J, Malaty IA. Smell and taste disorders in primary care. *Am Fam Physician*
370 2013;88(12):852-9.
- 371 [22] Pellegrino R, Walliczek-Dworschak U, Winter G, Hull D, Hummel T. Investigation of
372 chemosensitivity during and after an acute cold. *Int Forum Allergy Rhinol* 2017;7(2):185-
373 91.

Impact of COVID-19 on smell and taste

- 374 [23] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its
375 impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J*
376 2020.
- 377 [24] Cheng L, Chen J, Fu Q, He S, Li H, Liu Z, et al. Chinese Society of Allergy Guidelines for
378 Diagnosis and Treatment of Allergic Rhinitis. *Allergy Asthma Immunol Res*
379 2018;10(4):300-53.
- 380 [25] Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, et al. Epidemiology of chronic
381 rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. *Allergy*
382 2015;70(5):533-9.
- 383 [26] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response
384 in patients with COVID-19 in Wuhan, China. *Clin Infect Dis* 2020.
- 385 [27] Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit
386 from sustained lopinavir-combined regimen and the increase of eosinophil may predict the
387 outcome of COVID-19 progression. *Int J Infect Dis* 2020.
- 388 [28] Wang JH, Kwon HJ, Jang YJ. Detection of parainfluenza virus 3 in turbinate epithelial
389 cells of postviral olfactory dysfunction patients. *Laryngoscope* 2007;117(8):1445-9.
- 390 [29] Malhotra P, Luka A, McWilliams CS, Poeth KG, Schwartz R, Elfekey M, et al. Clinical
391 Features of Respiratory Viral Infections Among Inpatients at a Major US Tertiary Care
392 Hospital. *South Med J* 2016;109(8):481-6.
- 393 [30] Jaume F, Quinto L, Alobid I, Mullol J. Overuse of diagnostic tools and medications in
394 acute rhinosinusitis in Spain: a population-based study (the PROSINUS study). *BMJ Open*
395 2018;8(1):e018788.

Impact of COVID-19 on smell and taste

- 396 [31] Suzuki M, Saito K, Min WP, Vladau C, Toida K, Itoh H, et al. Identification of viruses in
397 patients with postviral olfactory dysfunction. *Laryngoscope* 2007;117(2):272-7.
- 398 [32] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and
399 imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center
400 study in Wenzhou city, Zhejiang, China. *J Infect* 2020;80(4):388-93.
- 401 [33] Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. Olfactory
402 and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). *Clin Infect Dis* 2020.
- 403 [34] Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of A case.
404 *Acta Neurol Taiwan* 2006;15(1):26-8.
- 405 [35] Hummel T, Landis BN, Huttenbrink KB. Smell and taste disorders. *GMS Curr Top*
406 *Otorhinolaryngol Head Neck Surg* 2011;10:Doc04.
- 407 [36] van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other
408 viral diseases into the central nervous system. *J Pathol* 2015;235(2):277-87.
- 409 [37] Mullol J, Marino-Sanchez F, Valls M, Alobid I, Marin C. The sense of smell in chronic
410 rhinosinusitis. *J Allergy Clin Immunol* 2020;145(3):773-6.
- 411 [38] Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the
412 CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.
413 *ACS Chem Neurosci* 2020;11(7):995-8.
- 414 [39] Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory
415 syndrome coronavirus infection causes neuronal death in the absence of encephalitis in
416 mice transgenic for human ACE2. *J Virol* 2008;82(15):7264-75.
- 417 [40] Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor
418 of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020;12(1):8.

Impact of COVID-19 on smell and taste

- 419 [41] Wu C, Zheng S, Chen Y, Zheng M. Single-cell RNA expression profiling of ACE2, the
420 putative receptor of Wuhan 2019-nCoV, in the nasal tissue. medRxiv 2020 DOI:
421 101101/2020021120022228 2020.
- 422 [42] Kumarhia D, He L, McCluskey LP. Inflammatory stimuli acutely modulate peripheral taste
423 function. *J Neurophysiol* 2016;115(6):2964-75.
- 424 [43] Henkin RI, Schmidt L, Velicu I. Interleukin 6 in hyposmia. *JAMA Otolaryngol Head Neck*
425 *Surg* 2013;139(7):728-34.
- 426 [44] Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss
427 in the era of COVID-19. *Int Forum Allergy Rhinol* 2020.
- 428 [45] Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. Intranasal
429 corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI
430 statement. *Allergy* 2020.
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439

Impact of COVID-19 on smell and taste

440 **Table 1. Demographic and clinical characteristics of 1,172 etiologically confirmed patients**

Characteristics	Total patients	Non-severe	Severe	P value
Subject, N (%)	1172 (100)	973 (83.0)	199 (17.0)	-
Gender, male, N (%)	577 (49.2)	480 (49.3)	97 (48.7)	0.94
Age, years, median (IQR)	61 (48, 68)	60 (46, 68)	64 (53, 70)	<0.01
Systemic signs and symptoms N (%)	-	-	-	-
Fever	921 (78.6)	758 (77.9)	163 (81.9)	0.21
Cough	767 (65.4)	625 (63.2)	142 (71.4)	0.06
Myalgia	172 (14.7)	136 (14.0)	36 (18.1)	0.13
Fatigue	285 (24.3)	226 (23.2)	59 (29.7)	0.05
Anorexia	274 (23.4)	214 (22.0)	60 (30.2)	0.01
Confusion	6 (0.5)	3 (0.3)	3 (1.5)	0.03
Dizziness	52 (4.4)	41 (4.2)	11 (5.5)	0.41
Any airway comorbidity, N (%)	203 (17.3)	179 (18.4)	24 (12.1)	0.03
AR	115 (9.8)	99 (10.2)	16 (8.0)	0.43
CRS	72 (6.1)	64 (6.6)	8 (4.5)	0.34
Asthma	29 (2.5)	25 (2.6)	4 (2.0)	0.81
COPD	10 (0.9)	10 (1.0)	0 (0)	0.23
Any nasal symptom, N (%)	342 (29.2)	275 (28.3)	67 (33.7)	0.15
Nasal obstruction, N (%)	101 (8.6)	82 (8.4)	19 (9.5)	0.58
Score, median (IQR)	3 (2, 4)	3 (2, 4)	3 (2, 5)	0.88
As first symptom, N (%)	2 (0.2)	1 (0.1)	1 (0.5)	0.31
Rhinorrhea, N (%)	120 (10.3)	100 (10.3)	20 (10.1)	0.99
Score, median (IQR)	3 (2, 4)	3 (2, 4)	2.5 (1.25, 3.75)	0.37
As first symptom, N (%)	9 (0.8)	8 (0.8)	1 (0.5)	0.99
Nasal itching, N (%)	57 (4.9)	45 (4.6)	12 (6.0)	0.37
Score, median (IQR)	2 (1.5, 3)	2 (2, 3.5)	2 (1, 2)	0.08
As first symptom, N (%)	1 (0.1)	1 (0.1)	0 (0)	0.99
Sneezing	129 (11.0)	104 (10.7)	25 (12.6)	0.46
Score, median (IQR)	2 (1, 3)	2 (1, 3)	2 (1, 2.5)	0.77
As first symptom, N (%)	1 (0.1)	1 (0.1)	0 (0)	0.99
Loss of smell	134 (11.4)	110 (11.3)	24 (12.1)	0.71
Score, median (IQR)	5 (4, 9)	5 (4, 8)	7.5 (3.25, 10)	0.37
As first symptom, N (%)	3 (0.3)	3 (0.3)	0 (0)	0.99
Loss of smell recovered , N (%)	110 (82.1%)	90 (81.8%)	20 (83.3%)	0.99
Recovery time, days, median (IQR)	8 (6, 13.25)	8 (5, 12.25)	8 (6.25, 14)	0.67
Loss of taste	242 (20.6)	199 (20.5)	43 (21.6)	0.70
Score, median (IQR)	6 (4, 8)	6 (4, 8)	7 (5, 9)	0.03
As first symptom, N (%)	5 (0.4)	4 (0.4)	1 (0.5)	0.99
Loss of taste recovered, N (%)	231 (95.5%)	190 (95.5%)	41 (95.3%)	0.99
Recovery time, days, median (IQR)	7 (5, 14)	7 (5, 14)	7 (5, 14.5)	0.76

441 Abbreviations: IQR, interquartile range; AR, allergic rhinitis, CRS, chronic rhinosinusitis; COPD, chronic
442 obstructive pulmonary disease. Data are presented as medians and interquartile ranges (IQR) for continuous
443 variables and numbers with percentage for categorical variables. P values were calculated from Kruskal-
444 Wallis, χ^2 test or Fisher's exact test.

445

Impact of COVID-19 on smell and taste

446 **Table 2. The comparison of 242 patients with different severity of loss of taste**

Characteristics	Mild (0-3)	Moderate (4-7)	Severe (8-10)	P value
Subject, N (%)	46 (19.0)	118 (48.8)	78 (32.2)	-
Gender, male, N (%)	21 (45.7)	59 (50.0)	39 (50.0)	0.16
Age, years, median (IQR)	55 (42, 67)	58.5 (43.75, 67)	58.5 (48.5, 66)	0.88
Severe cases, N (%)	7 (15.2)	15 (12.7)	21 (26.9) [#]	0.03
Loss of taste recovered, N (%)	45 (97.8)	110 (93.2)	76 (97.4)	0.26
Recovery time, days, median (IQR)	5 (3.5, 8)	8 (6, 13.25)**	10 (5, 15)**	<0.01
Any airway comorbidity, N (%)	6 (13.0)	26 (22.0)	13 (16.7)	0.36
AR	2 (4.3)	12 (10.2)	9 (11.5)	0.39
CRS	3 (6.5)	10 (5.6)	4 (5.1)	0.66
Asthma	1 (2.2)	3 (2.5)	2 (2.6)	0.99
COPD	0 (0)	3 (2.5)	0 (0)	0.20
Systemic signs and symptoms, N (%)	-	-	-	-
Fever	37 (80.4)	101 (85.6)	66 (84.6)	0.71
Cough	29 (61.7)	78 (66.1)	53 (70.0)	0.77
Myalgia	7 (15.2)	18 (15.3)	10 (12.8)	0.88
Fatigue	12 (26.1)	34 (28.8)	18 (23.1)	0.80
Anorexia	12 (26.1)	30 (25.4)	18 (23.1)	0.91
Confusion	1 (2.2)	0 (0)	0 (0)	0.12
Dizziness	2 (4.3)	3 (2.5)	4 (5.1)	0.63
Laboratory results, median (IQR)	-	-	-	-
Blood routine, subject, N	46	118	78	-
White blood cell count, ×10 ⁹ /L	5.7 (3.8, 6.8)	5.7 (4.5, 7.5)	5.8 (4.6, 7.4)	0.48
Neutrophil count, ×10 ⁹ /L	3.5 (2.6, 5.6)	3.8 (2.7, 5.5)	4.0 (2.8, 5.5)	0.96
Neutrophil percentage	66.8 (57.0, 75.0)	64.1 (57.3, 72.6)	66.8 (58.7, 73.0)	0.88
Lymphocyte count, ×10 ⁹ /L	1.1 (0.8, 2.0)	1.3 (0.9, 1.7)	1.2 (0.9, 1.6)	0.80
Lymphocyte percentage	23.1 (18, 31.8)	22.8 (16, 30.4)	21.7 (15.4, 28.7)	0.53
Monocyte count, ×10 ⁹ /L	0.5 (0.4, 0.6)	0.5 (0.4, 0.6)	0.5 (0.4, 0.7)	0.33
Monocyte percentage	8.5 (6.1, 11.4)	9.0 (7.0, 11.1)	9.5 (7.8, 10.6)	0.33
Eosinophil count, ×10 ⁹ /L	0.03 (0, 0.08)	0.06 (0.01, 0.11)	0.04 (0, 0.09)	0.14
Eosinophil percentage	0.4 (0, 1.2)	0.95 (0.2, 1.8)	0.6 (0, 1.7)	0.07
Platelet count, ×10 ⁹ /L	227 (187.8, 312)	252 (195, 314)	260 (190.8, 328)	0.27
Hemoglobin, g/L	128 (114.8, 137.5)	129 (113.8, 137)	129 (120, 141.3)	0.36
Liver and renal function test, subject, N	46	118	78	-
Alanine aminotransferase, U/L	22.5 (13, 35.3)	24.5 (16.8, 44)	29 (17, 43)	0.15
Aspartate aminotransferase, U/L	24.5 (19, 35)	21 (18, 34)	26.5 (19, 37.5)	0.30
Albumin, g/L	37.2 (33.1, 41.8)	36.7 (32.7, 40.2)	35.1 (32.3, 37.6)	0.08
Globulin, g/L	32.2 (29.3, 34.9)	32.4 (22.2, 35.8)	33.2 (29.8, 36.5)	0.48
Alkaline phosphatase, U/L	58 (50, 72.75)	63 (55, 80.25)	60 (52.25, 81.5)	0.15
Total bilirubin, μmol/L	8.4 (5.6, 13)	8.4 (6.4, 11.7)	8.8 (7, 11.4)	0.83
Lactose dehydrogenase, U/L	229.5 (179.5, 305.8)	239.5 (197, 300)	276.5 (224.5, 347.5) ^{*#}	0.04
Urea, mmol/L	4.3 (3.2, 5.7)	4.1 (3.3, 5.2)	3.75 (3.2, 4.83)	0.88
Creatinine, μmol/L	67.5 (59, 77)	69 (55, 82)	65.5 (56, 81)	0.98
Urine acid, μmol/L	276.9 (222.8, 338.2)	248 (190.7, 327.5)	241.4 (201.3, 293.8)	0.13
Glomerular filtration, ml/min/1.73m ²	93.3 (82.9, 109.5)	95.7 (83.9, 107.9)	94.2 (83.75, 106.1)	0.91
Electrolytes, subject, N	46	118	78	-
K ⁺ , mmol/L	4.2 (3.9, 4.6)	4.2 (3.9, 4.5)	4.1 (3.8, 4.4)	0.15

Impact of COVID-19 on smell and taste

Na ⁺ , mmol/L	139.4 (137.8, 141.6)	140.5 (138.2, 142)	139.5 (137.7, 141.3)	0.31
Cl ⁻ , mmol/L	100.8 (99, 103)	101.6 (99.1, 103.7)	100.8 (98.1, 103.1)	0.34
Ca ⁺ , mmol/L	2.14 (2.04, 2.24)	2.16 (2.08, 2.25)	2.15 (2.09, 2.22)	0.64
ESR, mm/H	25 (16.75, 58)	32 (13, 60)	39 (18, 64.75)	0.53
CRP, mg/L	4.65 (1.43, 29.6)	4.4 (1.2, 34)	7.5 (1.85, 42.85)	0.33
Cardiac troponin I, pg/mL	2.5 (1.9, 6.9)	2.9 (1.9, 7)	3.5 (1.9, 6.9)	0.81
Inflammatory mediators, subject, N	35	99	72	-
Ferritin, ug/L	467.7 (183, 633.5)	531.1 (294, 827.8)	576.7 (310.8, 1268)	0.21
Interleukin-10, pg/mL	5 (5, 5)	5 (5, 5)	5 (5, 5)	0.25
Interleukin-1 β , pg/mL	5 (5, 5)	5 (5, 5)	5 (5, 5)	0.55-
Interleukin-2 receptor, U/mL	465 (242, 624)	498 (376, 706)	571 (362.8, 792.5)	0.13
Interleukin-6, pg/mL	3.7 (1.7, 14.9)	3.8 (1.9, 10.5)	8.1 (2.3, 23.8)*#	0.03
Interleukin-8, pg/mL	6.5 (5, 10.5)	10.4 (5.5, 19.5)*	9.9 (5.3, 18.7)*	0.04
Tumor necrosis factor, pg/mL	7 (5.2, 9.7)	7 (5.1, 9.1)	7.9 (5.1, 10.9)	0.32
Procalcitonin, ng/mL	0.05 (0.03, 0.07)	0.05 (0.03, 0.08)	0.05 (0.02, 0.09)	0.98
Immunoglobulins and complements, subject, N	11	43	25	-
IgA, g/L	2.2 (1.6, 3.1)	2.2 (1.8, 2.6)	2.2 (1.6, 2.5)	0.97
IgG, g/L	10.6 (9.2, 11.6)	11.1 (9.6, 13.2)	11.6 (10, 13.6)	0.51
IgM, g/L	0.79 (0.64, 0.96)	1 (0.79, 1.3)	0.91 (0.65, 1.4)	0.12
C3, g/L	1 (0.83, 1.13)	0.86 (0.78, 1)	0.9 (0.74, 1.07)	0.34
C4, g/L	0.24 (0.22, 0.36)	0.22 (0.18, 0.28)	0.26 (0.2, 0.3)	0.16

447 Abbreviations, IQR, interquartile range; AR, allergic rhinitis, CRS, chronic rhinosinusitis; COPD, chronic
 448 obstructive pulmonary disease; ERS, erythrocyte sedimentation rate; CRP, C-reactive protein; Ig,
 449 immunoglobulin; C, complement. Data is presented as medians and interquartile ranges (IQR) for
 450 continuous variables and numbers with percentage for categorical variables. *P* values were calculated from
 451 Kruskal-Wallis, χ^2 test or Fisher's exact test. “*”, vs mild, *P* < 0.05, “***”, vs mild, *P* < 0.01, “#”, vs
 452 moderate, *P* < 0.05.

453

454

455

456

457

458

Impact of COVID-19 on smell and taste

459 **Table 3. The comparison of 134 patients with different severity of loss of smell**

Characteristic	Mild (0-3)	Moderate (4-7)	Severe (8-10)	P value
Subject, N (%)	32 (23.9)	48 (35.8)	54 (40.3)	-
Gender, male, N (%)	10 (31.3)	17 (35.4)	27 (50.0)	0.16
Age, years, median (IQR)	58 (49.25, 63.75)	57 (46, 68)	57.5 (42.25, 65.25)	0.82
Severe cases, N	6 (18.8)	6 (12.5)	12 (22.2)	0.44
Loss of smell recovered, N (%)	28 (87.5)	36 (75.0)	46 (85.2)	0.37
Recovery time, days, Median (IQR)	7 (5, 14)	7 (5.25, 10)	10 (7, 17.5)	0.08
Any airway comorbidity	8 (25.0)	10 (20.8)	9 (16.7)	0.64
AR	2 (6.3)	5 (10.4)	7 (13.0)	0.61
CRS	3 (9.4)	3 (6.3)	3 (5.6)	0.78
Asthma	3 (9.4)	1 (2.1)	0 (0)*	0.04
COPD	0 (0)	1 (2.1)	0 (0)	0.45
Systemic signs and symptoms	-	-	-	-
Fever	22 (68.8)	35 (72.9)	44 (81.5)	0.37
Cough	23 (71.9)	32 (66.7)	88 (65.7)	0.58
Myalgia	9 (28.1)	8 (16.7)	7 (13.0)	0.20
Fatigue	13 (40.6)	12 (25.0)	11 (20.4)	0.11
Anorexia	4 (12.5)	11 (22.9)	15 (27.8)	0.26
Confusion	0 (0)	0 (0)	0 (0)	-
Dizziness	2 (6.3)	3 (6.3)	4 (7.4)	0.97
Laboratory results	-	-	-	-
Blood routine, subject, N	32	48	54	-
White blood cell count, $\times 10^9/L$	5.1 (3.7, 6.5)	5.7 (4.6, 7.5)	5.8 (4.5, 7.8)	0.08
Neutrophil count, $\times 10^9/L$	2.9 (2.1, 5.0)	3.7 (2.7, 5.2)	4.2 (2.8, 5.4)	0.09
Neutrophil percentage	61.2 (53.0, 73.1)	64.1 (57.1, 74.8)	70.2 (58.6, 74.7)	0.33
Lymphocyte count, $\times 10^9/L$	1.3 (0.8, 1.6)	1.3 (1.0, 1.7)	1.3 (0.9, 1.6)	0.77
Lymphocyte percentage	26.2 (17.3, 34.2)	24.9 (16.2, 31.2)	22.2 (16.2, 27.0)	0.46
Monocyte count, $\times 10^9/L$	0.4 (0.4, 0.5)	0.5 (0.4, 0.6)	0.5 (0.4, 0.7)	0.09
Monocyte percentage	9.0 (7.2, 10.9)	8.9 (7.0, 10.1)	8.5 (6.5, 10.5)	0.67
Eosinophil count, $\times 10^9/L$	0.03 (0, 0.1)	0.05 (0.02, 0.08)	0.04 (0.01, 0.09)	0.61
Eosinophil percentage	0.85 (0, 1.8)	0.75 (0.3, 1.7)	0.75 (0.3, 1.7)	0.89
Platelet count, $\times 10^9/L$	232.5 (143.8, 264.5)	259.5 (199.5, 308)	238 (188.5, 316)	0.14
Hemoglobin, g/L	125.5 (113, 135.3)	125.5 (114, 134.8)	128.5 (119.5, 143.3)	0.12
Liver and renal function test, subject, N	32	48	54	-
Alanine aminotransferase, U/L	18 (13, 49)	20 (12, 31)*	29 (17, 43)	0.04
Aspartate aminotransferase, U/L	21.5 (18.3, 31.8)	20.5 (16, 29)	25 (16, 33.3)	0.48
Albumin, g/L	37.1 (32.1, 39.9)	36.6 (31.5, 41)	34.5 (32.4, 38.7)	0.81
Globulin, g/L	31.8 (29.4, 34.4)	32.4 (26.2, 38.9)	33.1 (28.9, 36)	0.89
Alkaline phosphatase, U/L	67.5 (55, 81.3)	59 (52, 74.3)	58.5 (50, 79.3)	0.26
Total bilirubin, $\mu\text{mol/L}$	8.4 (6.7, 10.1)	9.7 (7.3, 11.6)	8.6 (6.3, 11.6)	0.68
Lactose dehydrogenase, U/L	236 (194, 298.8)	231.5 (189.3, 267.5)	264.5 (188.8, 367.3)	0.27
Urea, mmol/L	3.8 (3.4, 4.4)	4.5 (3.3, 5.2)	4.0 (3.3, 5.5)	0.47
Creatinine, $\mu\text{mol/L}$	51 (37, 59)	62 (53, 78.3)	64.5 (55, 80)	0.43
Urine acid, $\mu\text{mol/L}$	242.9 (182.1, 302.5)	271 (223.5, 327.1)	233.5 (198.5, 282.3)	0.11
Glomerular filtration, ml/min/1.73m ²	97.1 (90.4, 109.4)	93.4 (78.9, 107.6)	95.7 (88.1, 110.1)	0.54
Electrolytes, subject, N	32	48	54	-
K ⁺ , mmol/L	4.0 (3.8, 4.2)	4.1 (3.7, 4.3)	4.1 (3.7, 4.5)	0.56
Na ⁺ , mmol/L	140.9 (137.6, 142.3)	139.8 (138.1, 141.8)	139.4 (137.7, 140.9)	0.17
Cl ⁻ , mmol/L	101.2 (99.3, 104.3)	101.9 (100.3, 103.7)	101 (98, 103.2)	0.41

Impact of COVID-19 on smell and taste

Ca ⁺ , mmol/L	2.15 (2.04, 2.26)	2.20 (2.08, 2.27)	2.15 (2.08, 2.23)	0.46
Cardiac troponin I, pg/mL	4.7 (3, 13.9)	6.6 (2.7, 11.8)	5 (3.2, 8.2)	0.84
ESR, mm/H	48 (22, 67)	38.5 (12, 59.3)	26.5 (10.5, 53)	0.15
CRP, mg/L	14.1 (2, 35.8)	4 (1.6, 28.4)	5.7 (1.5, 42.7)	0.57
Inflammatory mediators, subject, N	26	45	48	-
Ferritin, ug/L	515.9 (205.5, 1304)	426.7 (228.1, 645.3)	663.1 (328.3, 1050)	0.23
Interleukin-10, pg/mL	5 (5, 5.3)	5 (5, 5)*	5 (5, 5.7)	0.04
Interleukin-1 β , pg/mL	5 (5, 5)	5 (5, 5)	5 (5, 5)	0.24
Interleukin-2 receptor, U/mL	523 (344, 751)	428 (279, 688)	554.5 (322.3, 711.3)	0.47
Interleukin-6, pg/mL	3.8 (2.1, 13.6)	3.7 (1.5, 8.6)	4.1 (1.6, 20.0)	0.46
Interleukin-8, pg/mL	7.7 (5, 16.2)	9.1 (5.2, 12.3)	10.2 (5.1, 21.8)	0.42
Tumor necrosis factor, pg/mL	8.6 (5.7, 9.9)	6 (4.7, 7.2)*	8.0 (5.6, 10.3)	<0.01
Procalcitonin, ng/mL	0.05 (0.04, 0.09)	0.04 (0.02, 0.07)	0.05 (0.03, 0.09)	0.35
Immunoglobulins and complements, subject, N	8	17	21	-
IgA, g/L	2.1 (1.9, 2.3)	2.2 (1.2, 2.8)	2.3 (1.6, 2.8)	0.83
IgG, g/L	10.5 (9.5, 15.9)	12.9 (10.8, 15.5)	12.5 (10.6, 14.5)	0.55
IgM, g/L	0.94 (0.81, 1.2)	1 (0.82, 1.34)	0.86 (0.67, 1.21)	0.56
C3, g/L	0.91 (0.72, 1.1)	0.89 (0.72, 0.97)	0.92 (0.78, 1.05)	0.68
C4, g/L	0.23 (0.19, 0.24)	0.18 (0.11, 0.21)	0.21 (0.16, 0.33)	0.94

460 Abbreviations, IQR, interquartile range; AR, allergic rhinitis, CRS, chronic rhinosinusitis; COPD, chronic
 461 obstructive pulmonary disease; ERS, erythrocyte sedimentation rate; CRP, C-reactive protein; Ig,
 462 immunoglobulin; C, complement. Data is presented as medians and interquartile ranges (IQR) for
 463 continuous variables and numbers with percentage for categorical variables. *P* values were calculated from
 464 Kruskal-Wallis, χ^2 test or Fisher's exact test. "***", vs mild, *P* < 0.05.

465

466

467

468

469

470

471

472

473

Impact of COVID-19 on smell and taste

474 **Figure Legends**

475 **Figure 1. The impact of coronavirus disease 2019 (COVID-19) on smell and taste.** (A) The
476 prevalence of self-reported loss of smell and taste in severe and non-severe COVID-19 patients.
477 The frequencies are indicated on the top of the columns. (B) The severity of self-reported loss of
478 smell and taste in severe and non-severe COVID-19 patients. Severity of self-reported loss of
479 smell and taste symptom was scored by patients on a numerical rating scale of 0-10, with 0 being
480 “no complaint whatsoever” and 10 being “the worst imaginable complaint. (C) The recovery
481 time of self-reported smell and taste dysfunction in severe and non-severe COVID-19 patients.
482 (D) The pattern of recovery time for patients with self-reported loss of smell and taste. The
483 frequencies are indicated on the top of columns. * $P < 0.05$ compared to non-severe COVID-19.

484

485 **Figure 2. The recovery time of patients with different severity of loss of smell and loss of**
486 **taste.** Severity of self-reported loss of smell and taste symptom was scored by patients on a
487 numerical rating scale of 0-10, with 0 being “no complaint whatsoever” and 10 being “the worst
488 imaginable complaint. ** $P < 0.01$ compared to mild loss of taste.


489

490 **Figure 3. Correlations between loss of taste scores and serum levels of IL-6 (A), IL-8 (B),**
491 **lactose dehydrogenase (LDH) (C).** Severity of self-reported loss of taste was scored by patients
492 on a numerical rating scale of 0-10, with 0 being “no complaint whatsoever” and 10 being “the
493 worst imaginable complaint.

494

Impact of COVID-19 on smell and taste

495 **Figure 1**




496

497

Impact of COVID-19 on smell and taste

498 **Figure 2**




499

500

Impact of COVID-19 on smell and taste

501 **Figure 3**



502